Gallbladder Cancer – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 1 PAGES: 110

More Info
									             Gallbladder Cancer – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1956IDB
                                                                                              Publication Date: April 2012




Gallbladder Cancer – Pipeline Review, H1 2012                                                 GMDHC1956IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Gallbladder Cancer – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 8
    List of Figures ................................................................................................................................................................................ 8
Introduction......................................................................................................................................................................................... 9
    Global Markets Direct Report Coverage ........................................................................................................................................ 9
Gallbladder Cancer Overview........................................................................................................................................................... 10
Therapeutics Development............................................................................................................................................................... 11
    An Overview of Pipeline Products for Gallbladder Cancer .......................................................................................................... 11
Gallbladder Cancer Therapeutics under Development by Companies ............................................................................................. 13
Gallbladder Cancer Therapeutics under Investigation by Universities/Institutes .............................................................................. 14
Late Stage Products ......................................................................................................................................................................... 18
    Comparative Analysis .................................................................................................................................................................. 18
Mid Clinical Stage Products.............................................................................................................................................................. 19
    Comparative Analysis .................................................................................................................................................................. 19
Early Clinical Stage Products ........................................................................................................................................................... 20
    Comparative Analysis .................................................................................................................................................................. 20
Gallbladder Cancer Therapeutics – Products under Development by Companies ........................................................................... 21
Gallbladder Cancer Therapeutics – Products under Investigation by Universities/Institutes ............................................................ 22
Companies Involved in Gallbladder Cancer Therapeutics Development.......................................................................................... 24
    AstraZeneca PLC ........................................................................................................................................................................ 24
Gallbladder Cancer – Therapeutics Assessment ............................................................................................................................. 25
    Assessment by Monotherapy Products ....................................................................................................................................... 25
    Assessment by Combination Products ........................................................................................................................................ 26
    Assessment by Route of Administration ...................................................................................................................................... 27
    Assessment by Molecule Type .................................................................................................................................................... 29
Drug Profiles..................................................................................................................................................................................... 31
    Tarceva - Drug Profile ................................................................................................................................................................. 31
         Product Description................................................................................................................................................................. 31
         Mechanism of Action ............................................................................................................................................................... 31
         R&D Progress ......................................................................................................................................................................... 31
    Gemcitabine + Oxaliplatin + Erlotinib - Drug Profile..................................................................................................................... 33
         Product Description................................................................................................................................................................. 33
         Mechanism of Action ............................................................................................................................................................... 33
         R&D Progress ......................................................................................................................................................................... 33
    Gemzar + Xeloda - Drug Profile .................................................................................................................................................. 35
         Product Description................................................................................................................................................................. 35
         Mechanism of Action ............................................................................................................................................................... 35
         R&D Progress ......................................................................................................................................................................... 35
    Gemcitabine + Radiation Therapy - Drug Profile ......................................................................................................................... 37
         Product Description................................................................................................................................................................. 37
         Mechanism of Action ............................................................................................................................................................... 37
         R&D Progress ......................................................................................................................................................................... 37



Gallbladder Cancer – Pipeline Review, H1 2012                                                                                                      GMDHC1956IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Gallbladder Cancer – Pipeline Review, H1 2012




    BAY 43-9006 - Drug Profile ......................................................................................................................................................... 39
        Product Description................................................................................................................................................................. 39
        Mechanism of Action ............................................................................................................................................................... 39
        R&D Progress ......................................................................................................................................................................... 39
    Capecitabine - Drug Profile ......................................................................................................................................................... 40
        Product Description................................................................................................................................................................. 40
        Mechanism of Action ............................................................................................................................................................... 40
        R&D Progress ......................................................................................................................................................................... 40
    Gemcitabine + Capecitabine - Drug Profile ................................................................................................................................. 41
        Product Description................................................................................................................................................................. 41
        Mechanism of Action ............................................................................................................................................................... 41
        R&D Progress ......................................................................................................................................................................... 41
    Erlotinib + Gemcitabine + Oxaliplatin - Drug Profile.................................................................................................................... 42
        Product Description................................................................................................................................................................. 42
        Mechanism of Action ............................................................................................................................................................... 42
        R&D Progress ......................................................................................................................................................................... 43
    Carcinoembryonic Antigen RNA-Pulsed DC Cancer Vaccine - Drug Profile ............................................................................... 44
        Product Description................................................................................................................................................................. 44
        Mechanism of Action ............................................................................................................................................................... 44
        R&D Progress ......................................................................................................................................................................... 44
    Gemcitabine + Cisplatin - Drug Profile......................................................................................................................................... 46
        Product Description................................................................................................................................................................. 46
        Mechanism of Action ............................................................................................................................................................... 46
        R&D Progress ......................................................................................................................................................................... 46
    Davanat + 5-Fluorouracil - Drug Profile ....................................................................................................................................... 47
        Product Description................................................................................................................................................................. 47
        Mechanism of Action ............................................................................................................................................................... 47
        R&D Progress ......................................................................................................................................................................... 47
    Dolastatin 10 - Drug Profile.......................................................................................................................................................... 49
        Product Description................................................................................................................................................................. 49
        Mechanism of Action ............................................................................................................................................................... 49
        R&D Progress ......................................................................................................................................................................... 49
    Capecitabine + Gemcitabine + Radiation Therapy - Drug Profile ................................................................................................ 50
        Product Description................................................................................................................................................................. 50
        Mechanism of Action ............................................................................................................................................................... 50
        R&D Progress ......................................................................................................................................................................... 51
    Herceptin - Drug Profile ............................................................................................................................................................... 52
        Product Description................................................................................................................................................................. 52
        Mechanism of Action ............................................................................................................................................................... 52
        R&D Progress ......................................................................................................................................................................... 52
    Recombinant Interleukin-12 - Drug Profile ................................................................................................................................... 53
        Product Description................................................................................................................................................................. 53
        Mechanism of Action ............................................................................................................................................................... 53
        R&D Progress ......................................................................................................................................................................... 53


Gallbladder Cancer – Pipeline Review, H1 2012                                                                                                 GMDHC1956IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                              Page(3)
Gallbladder Cancer – Pipeline Review, H1 2012




    Gemcitabine + Capecitabine - Drug Profile ................................................................................................................................. 55
        Product Description................................................................................................................................................................. 55
        Mechanism of Action ............................................................................................................................................................... 55
        R&D Progress ......................................................................................................................................................................... 55
    Gemcitabine + Oxaliplatin + Sorafenib - Drug Profile .................................................................................................................. 56
        Product Description................................................................................................................................................................. 56
        Mechanism of Action ............................................................................................................................................................... 56
        R&D Progress ......................................................................................................................................................................... 56
    Zactima + Gemzar - Drug Profile ................................................................................................................................................. 57
        Product Description................................................................................................................................................................. 57
        Mechanism of Action ............................................................................................................................................................... 57
        R&D Progress ......................................................................................................................................................................... 57
    Gemcitabine + Cisplatin + Sorafenib - Drug Profile ..................................................................................................................... 59
        Product Description................................................................................................................................................................. 59
        Mechanism of Action ............................................................................................................................................................... 59
        R&D Progress ......................................................................................................................................................................... 59
    Gemcitabine + Cisplatin + S-1 - Drug Profile ............................................................................................................................... 60
        Product Description................................................................................................................................................................. 60
        Mechanism of Action ............................................................................................................................................................... 60
        R&D Progress ......................................................................................................................................................................... 60
    Recombinant Fowlpox-CEA(6D) + GM-CSF - Drug Profile ........................................................................................................ 62
        Product Description................................................................................................................................................................. 62
        Mechanism of Action ............................................................................................................................................................... 62
        R&D Progress ......................................................................................................................................................................... 62
    Cyclophosphamide + Fludarabine + Anti-Thymocyte Globulin + Cyclosporine + Peripheral Blood Stem Cell Transplantation +
    Therapeutic Allogeneic Lymphocytes - Drug Profile .................................................................................................................... 63
        Product Description................................................................................................................................................................. 63
        Mechanism of Action ............................................................................................................................................................... 63
        R&D Progress ......................................................................................................................................................................... 64
    Gemcitabine + Sorafenib - Drug Profile ....................................................................................................................................... 65
        Product Description................................................................................................................................................................. 65
        Mechanism of Action ............................................................................................................................................................... 65
        R&D Progress ......................................................................................................................................................................... 65
    Avastin + Tarceva - Drug Profile .................................................................................................................................................. 66
        Product Description................................................................................................................................................................. 66
        Mechanism of Action ............................................................................................................................................................... 66
        R&D Progress ......................................................................................................................................................................... 66
    Eloxatin + Xeloda - Drug Profile .................................................................................................................................................. 68
        Product Description................................................................................................................................................................. 68
        Mechanism of Action ............................................................................................................................................................... 68
        R&D Progress ......................................................................................................................................................................... 68
    Gemcitabine + Docetaxel + 5-Fluorouracil + Radiation Therapy - Drug Profile ........................................................................... 69
        Product Description................................................................................................................................................................. 69
        Mechanism of Action ............................................................................................................................................................... 69



Gallbladder Cancer – Pipeline Review, H1 2012                                                                                                 GMDHC1956IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                              Page(4)
Gallbladder Cancer – Pipeline Review, H1 2012




        R&D Progress ......................................................................................................................................................................... 70
    S-1 + Gemcitabine - Drug Profile ................................................................................................................................................. 71
        Product Description.........
								
To top